瑞普生物(300119) - 2022 Q1 - 季度财报

Financial Performance - Revenue for Q1 2022 was CNY 390,806,576.59, a decrease of 30.20% compared to CNY 559,913,601.19 in the same period last year[2] - Net profit attributable to shareholders was CNY 72,205,916.82, down 37.94% from CNY 116,352,232.21 year-on-year[2] - Basic earnings per share decreased by 46.62% to CNY 0.1564 from CNY 0.2930 in the previous year[2] - Total operating revenue for Q1 2022 was CNY 390,806,576.59, a decrease of 30.2% compared to CNY 559,913,601.19 in the same period last year[28] - Net profit attributable to the parent company for Q1 2022 was CNY 72,205,916.82, a decline of 38.0% from CNY 116,352,232.21 in Q1 2021[29] - The total comprehensive income attributable to the parent company was CNY 72,205,916.82, down from CNY 116,352,232.21 in the previous period, representing a decrease of approximately 38%[30] Cash Flow and Assets - Net cash flow from operating activities was negative CNY 54,538,255.13, a decline of 232.26% compared to CNY 41,237,174.09 in the same period last year[2] - Cash inflow from operating activities totaled CNY 348,762,765.72, a decrease of about 26.5% from CNY 474,225,967.03 in the previous year[34] - Cash outflow from operating activities was CNY 403,301,020.85, down from CNY 432,988,792.94, indicating a reduction of approximately 6.5%[34] - Total assets at the end of the reporting period were CNY 5,618,731,855.50, a decrease of 1.27% from CNY 5,690,781,226.40 at the end of the previous year[2] - As of the end of the reporting period, the company’s total current assets amounted to approximately CNY 2.86 billion, a decrease from CNY 3.06 billion at the beginning of the year[25] - The company’s cash and cash equivalents decreased from CNY 1.31 billion at the beginning of the year to approximately CNY 717 million[25] Investment and R&D - The company invested a total of 33.85 million CNY in R&D, accounting for 8.7% of its revenue[16] - Research and development expenses for Q1 2022 amounted to CNY 21,549,970.45, compared to CNY 24,177,319.41 in the previous year, reflecting a decrease of 10.8%[29] - The company is in the process of applying for product approval numbers for several new veterinary drugs, enhancing its product pipeline and market competitiveness[18] - The company obtained 1 new veterinary drug registration certificate and 34 product approval numbers during the reporting period[16] Shareholder Information - The top shareholder, Li Shoujun, holds 35.76% of the shares, amounting to 167,474,479 shares[9] - The second-largest shareholder, Liang Wu, owns 5.06% of the shares, totaling 23,716,898 shares[9] - The company has a total of 22,844 common shareholders as of the end of the reporting period[9] Market Challenges - The company faced challenges in the pig farming sector due to low prices and reduced demand for pork, leading to ongoing capacity reduction[13] - The poultry farming sector experienced significant capacity reduction due to prolonged losses and rising feed costs[13] Product Development - The company has not reported any new product developments or market expansions in the current quarter[13] - The clindamycin phosphate granules project has received approval, offering a highly effective oral medication for skin wounds and infections in dogs[16] - The compound nystatin ointment project has also received approval, designed to treat various ear conditions in dogs and cats[16] - The imidacloprid and moxidectin topical solution for dogs has been approved, providing a comprehensive solution for 28 types of internal and external parasites[16] - The imidacloprid and moxidectin topical solution for cats has received approval, enhancing the company's product line in the pet healthcare market[16] - The company emphasizes innovation and aims to maintain its leading position in the pet healthcare sector through continuous R&D investment[16] - The new products are expected to significantly enhance the company's competitiveness and market share in the pet healthcare industry[16] Financial Ratios - The company's debt-to-asset ratio stood at 22.4%, indicating a strong financial position[13]